IVT PCV-25
/ Inventprise
- LARVOL DELTA
Home
Next
Prev
1 to 12
Of
12
Go to page
1
April 16, 2025
Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy Infants
(clinicaltrials.gov)
- P2 | N=421 | Active, not recruiting | Sponsor: Inventprise Inc. | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2025 ➔ Dec 2026
Enrollment closed • Trial completion date • Infectious Disease • Pneumococcal Infections
January 29, 2025
Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy Infants
(clinicaltrials.gov)
- P2 | N=420 | Recruiting | Sponsor: Inventprise Inc. | Not yet recruiting ➔ Recruiting
Enrollment open • Infectious Disease • Pneumococcal Infections
January 24, 2025
Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy Infants
(clinicaltrials.gov)
- P2 | N=420 | Not yet recruiting | Sponsor: Inventprise Inc.
New P2 trial • Infectious Disease • Pneumococcal Infections
February 25, 2024
PUTATIVE NOVEL SEROTYPES IN SEROGROUP 33
(ISPPD 2024)
- "Background: Serotype 33F, a well-recognized invasive pneumococcal serotype is included in the higher valent pneumococcal conjugate vaccines (PCV) like PCV15, PCV20, PCV24, and IVT-25... While the prevalence of newly described serotype 33E is low within the GPS database, we identified four putative novel serotypes in serogroup 33 that warrant further characterization."
Infectious Disease • Pneumococcal Infections
February 25, 2024
GENOMIC CHARACTERISATION OF INVASIVE STREPTOCOCCUS PNEUMONIAE IN CHILDREN IN SLOVENIA
(ISPPD 2024)
- "In the post-PCV13 population, higher-valent PCV15, PCV20, PCV24 and IVT-25 will increase serotype coverage to 47.3% (44/93), 59.1% (55/93), 60.2% (56/93), 74.2% (69/93), respectively. In Slovenia, proportional decreases in vaccine serotypes among IPD cases in children after the introduction of PCV10/PCV13 was observed. Further surveillance is needed to confirm the emerging serotypes."
Clinical • Infectious Disease • Pneumococcal Infections • Pneumonia
February 25, 2024
GENOMIC CHARACTERISATION OF STREPTOCOCCUS PNEUMONIAE POPULATION CAUSING INVASIVE DISEASE IN LEBANON
(ISPPD 2024)
- "Higher valency vaccines such as PCV24 (68%; 56/82) and IVT25 would offer the highest serotype coverage in the PCV13 period. Vaccine effectiveness was demonstrated by the change in pneumococcal serotypes post-PCV13 introduction."
Clinical • CNS Disorders • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases • Septic Shock
December 13, 2023
Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine
(clinicaltrials.gov)
- P2 | N=220 | Active, not recruiting | Sponsor: Inventprise Inc. | Recruiting ➔ Active, not recruiting
Enrollment closed • Infectious Disease • Pneumococcal Infections
October 27, 2023
Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine
(clinicaltrials.gov)
- P2 | N=220 | Recruiting | Sponsor: Inventprise Inc. | Not yet recruiting ➔ Recruiting
Enrollment open • Infectious Disease • Pneumococcal Infections
October 11, 2023
Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine
(clinicaltrials.gov)
- P2 | N=220 | Not yet recruiting | Sponsor: Inventprise Inc.
New P2 trial • Infectious Disease • Pneumococcal Infections
August 30, 2023
IVT PCV-25: Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine
(clinicaltrials.gov)
- P1 | N=65 | Completed | Sponsor: Inventprise Inc. | Recruiting ➔ Completed | Phase classification: P1/2 ➔ P1 | N=520 ➔ 65 | Trial completion date: Feb 2025 ➔ Jul 2023 | Trial primary completion date: Sep 2024 ➔ Jul 2023
Enrollment change • Phase classification • Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections
November 09, 2022
IVT PCV-25: Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine
(clinicaltrials.gov)
- P1/2 | N=520 | Recruiting | Sponsor: Inventprise Inc. | Not yet recruiting ➔ Recruiting
Enrollment open • Infectious Disease • Pneumococcal Infections
September 14, 2022
IVT PCV-25: Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine
(clinicaltrials.gov)
- P1/2 | N=520 | Not yet recruiting | Sponsor: Inventprise Inc.
New P1/2 trial • Infectious Disease • Pneumococcal Infections
1 to 12
Of
12
Go to page
1